Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. We aimed to estimate the cost-effectiveness of sorafenib and TACE in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Chen, Shuling, Peng, Zhenwei, Wei, Mengchao, Liu, Weifeng, Dai, Zihao, Wang, Haibo, Mei, Jie, Cheong, Mingfong, Zhang, Hanmei, Kuang, Ming
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887167/
https://ncbi.nlm.nih.gov/pubmed/29621988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4308-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires